Home › Research › How common it is
Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts
Wei Zhang, Juan I. Young, Lissette Gomez, Michael A. Schmidt, David Lukacsovich, Brian W. Kunkle, X. Steven Chen, Eden R. Martin et al.. Alzheimer s & Dementia, 2025-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Meta-analysis identified 44 CpGs and 44 differentially methylated regions consistently associated with time to dementia in both cohorts. Our integrative analysis identified early processes in dementia, such as immune responses and metabolic dysfunction. Furthermore, we developed a methylation-based risk score, which successfully predicted future cognitive decline in an independent validation set, even after accounting for age, sex, apolipoprotein E ε4, years of education, baseline diagnosis, and baseline Mini-Mental State Examination score. DNAm offers a promising source as a biomarker for dementia risk assessment. HIGHLIGHTS: Blood DNA methylation (DNAm) differences at individual CpGs and differentially methylated regions are significantly associated with incident dementia. Pathway analysis revealed DNAm differences associated with incident dementia are significantly enriched in biological pathways involved in immune responses and metabolic processes. Out-of-sample validation analysis demonstrated that a methylation-based risk score successfully predicted future cognitive decline in an independent dataset, even after accounting for age, sex, apolipoprotein E ε4, years of education, baseline diagnosis, and baseline Mini-Mental State Examination score.
What this study adds
Evidence grade: High
This is a pooled review. A blood DNA methylation signature was consistently associated with time to dementia across two cohorts, and a methylation-based risk score predicted future cognitive decline in an independent validation set even after accounting for other factors. The authors describe DNA methylation as a promising source for dementia risk assessment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, W., Young, J. I., Gomez, L., Schmidt, M. A., Lukacsovich, D., Kunkle, B. W., et al. (2025). Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14496
Vancouver
Zhang W, Young JI, Gomez L, Schmidt MA, Lukacsovich D, Kunkle BW, et al. Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14496. PMID: 40133250.
BibTeX
@article{zhang2025-40133250,
author = {Zhang, Wei and Young, Juan I. and Gomez, Lissette and Schmidt, Michael A. and Lukacsovich, David and Kunkle, Brian W. and Chen, X. Steven and Martin, Eden R. and others},
title = {{Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.14496},
pmid = {40133250},
url = {https://doi.org/10.1002/alz.14496}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Meta-analysis identified 44 CpGs and 44 differentially methylated regions consistently associated with time to dementia in both cohorts.
- Our integrative analysis identified early processes in dementia, such as immune responses and metabolic dysfunction.
- Furthermore, we developed a methylation-based risk score, which successfully predicted future cognitive decline in an independent validation set, even after accounting for age, sex, apolipoprotein E ε4, years of education, baseline diagnosis, and baseline Mini-Mental State Examination score.
- DNAm offers a promising source as a biomarker for dementia risk assessment.
- HIGHLIGHTS: Blood DNA methylation (DNAm) differences at individual CpGs and differentially methylated regions are significantly associated with incident dementia.
Why it matters
A blood DNA methylation signature was consistently associated with time to dementia across two cohorts, and a methylation-based risk score predicted future cognitive decline in an independent validation set even after accounting for other factors. The authors describe DNA methylation as a promising source for dementia risk assessment.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designmeta-analysis
- Evidence strengthHigh
How this study scored 57/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Lily Wang: h-index 9 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Miami: institution h-index 998 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40133250) |
| Free to read | 2 / 2 | Free to read |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in How common it is from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.